Loganin

Catalog No.S3835 Batch:S383501

Print

Technical Data

Formula

C17H26O10

Molecular Weight 390.38 CAS No. 18524-94-2
Solubility (25°C)* In vitro DMSO 78 mg/mL (199.8 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Loganin (Loganoside) is an iridoid glycoside first isolated from the seeds of Strychnos nux-vomica, a member of the Loganiaceae family. It is a non-competitive inhibitor of BACE1 with IC50 of 47.97 μM an also inhibits AChE and BChE with IC50 values of 3.95 μM and 33.02 μM, respectively.
Targets
AChE [1]
(Cell-free assay)
BChE [1]
(Cell-free assay)
BACE1 [1]
(Cell-free assay)
3.95 μM 33.02 μM 47.97 μM
In vitro In SMN-deficient NSC34 cells, loganin increases cell viability, neurite length, and expressions of SMN, Gemin2, SMN-Gemin2 complex, p-Akt, p-GSK-3, p-CREB, BDNF and Bcl-2. Loganin attenuates H2O2-induced neuronal damage via suppressing MAPKs signals in SH-SY5Y cells[2]. Loganin may directly promote the differentiation and inhibit the apoptosis of MC3T3-E1 cells and indirectly reduce bone resorption. Loganin could directly enhance the function of osteoblasts and elevate their survival rate, indirectly inhibit the function of osteoclastd and reduce the number of osteoclastd via RANKL from osteoblastd[3].
In vivo Loganin provides benefits to SMA (pinal muscular atrophy) therapeutics via improving SMN (survival motor neuron) restoration, muscle strength and body weight. In type 2 diabetes mice, loganin not only lowers blood glucose but also attenuates hyperglycemia-induced inflammation, oxidative stress and apoptosis. Loganin improves spatial memory in streptozotocin-induced diabetic rats and exhibits antiamnesic activity in scopolamine-treated mice via acetylcholinesterase inhibition[2].

Protocol (from reference)

Cell Assay:[2]
  • Cell lines

    NSC34 cells

  • Concentrations

    0.01, 0.1, 1, 10 μM

  • Incubation Time

    48 h

  • Method

    --

Animal Study:[2]
  • Animal Models

    Transgenic mice expressing SMA-like phenotypes

  • Dosages

    15 mg/kg/day

  • Administration

    s.c.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.